Medicenna Therapeutics announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company’s failure to comply with the US$1.00 per share minimum bid price requirement. The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by executing a reverse stock split. The Company’s common shares will continue to trade on the Toronto Stock Exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDNA:
- Medicenna Announces Nasdaq Delisting and Cutback of Management Team
- Medicenna doses first patient in Phase 2 dose expansion of Phase 1/2 ABILITY
- Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
- Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
- Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer